Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema

The composite physiologic index (CPI) was derived to represent the extent of fibrosis on high-resolution computed tomography (HRCT), adjusting for emphysema in patients with idiopathic pulmonary fibrosis (IPF). We hypothesised that longitudinal change in CPI would better predict mortality than forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) or diffusing capacity of the lung for carbon monoxide (DL,CO) in all patients with IPF, and especially in those with combined pulmonary fibrosis and emphysema (CPFE). Cox proportional hazard models were performed on pulmonary function data from IPF patients at baseline (n = 321), 6 months (n = 211) and 12 months (n = 144). Presence of CPFE was determined by HRCT. A five-point increase in CPI over 12 months predicted subsequent mortality (HR 2.1, p = 0.004). At 12 months, a 10% relative decline in FVC, a 15% relative decline in DL,CO or an absolute increase in CPI of five points all discriminated median survival by 2.1 to 2.2 yrs versus patients with lesser change. Half our cohort had CPFE. In patients with moderate/severe emphysema, only a 10% decline in FEV1 predicted mortality (HR 3.7, p = 0.046). In IPF, a five-point increase in CPI over 12 months predicts mortality similarly to relative declines of 10% in FVC or 15% in DL,CO. For CPFE patients, change in FEV1 was the best predictor of mortality.

[1]  D. Coultas,et al.  Is idiopathic pulmonary fibrosis an environmental disease? , 2006, Proceedings of the American Thoracic Society.

[2]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[3]  J A Waldron,et al.  Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. , 1997, American journal of respiratory and critical care medicine.

[4]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[5]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[6]  D. Schwartz,et al.  Determinants of survival in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.

[7]  A. Nicholson,et al.  Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial , 2009, Respiratory research.

[8]  Meilan K. Han,et al.  Longitudinal Changes In The Composite Physiologic Index And Pulmonary Function In Patients With Idiopathic Pulmonary Fibrosis And Emphysema , 2010, ATS 2010.

[9]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[10]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[11]  T. Honda,et al.  Clinical characteristics of combined pulmonary fibrosis and emphysema , 2010, Respirology.

[12]  T. Hartman,et al.  Smoking-related interstitial lung diseases: a concise review. , 2001, The European respiratory journal.

[13]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[14]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[15]  R. Strawderman,et al.  Clinical significance of histological classification of idiopathic interstitial pneumonia , 2002, European Respiratory Journal.

[16]  F. Martinez,et al.  Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[17]  F. Martinez,et al.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[18]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[19]  F. Martinez,et al.  The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis , 2005, Annals of Internal Medicine.

[20]  H. Collard,et al.  Demystifying idiopathic interstitial pneumonia. , 2003, Archives of internal medicine.

[21]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[22]  D. Schwartz,et al.  The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. , 1991, The American review of respiratory disease.

[23]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[24]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[25]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[26]  P. Brillet,et al.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity , 2005, European Respiratory Journal.

[27]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.